peptable

Comparison

BPC-157 vs FOXO4-DRI

Function

While BPC-157 is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects111, FOXO4-DRI acts as a senolytic in preclinical models by promoting apoptosis of senescent cells, improving tissue function and healthspan measures in aged animals38.

Mechanism

While BPC-157 works as a synthetic 15-amino-acid fragment of a gastric cytoprotective protein that promotes angiogenesis and tissue protection primarily by modulating VEGFR2 signaling, Src/caveolin-1–dependent eNOS activation, and nitric oxide production111, FOXO4-DRI is a D-retro-inverso peptide derived from a FOXO4 region that competes with endogenous FOXO4 for binding to p53, thereby releasing p53 to trigger apoptosis selectively in senescent cells38.

Length and Sequence

BPC-157 is 15 amino acids long, whereas FOXO4-DRI is shorter as it has a length of amino acids. BPC-157 is made up of a sequence of Glycine, Glutamic acid, Proline, Proline, Proline, Glycine, Lysine, Proline, Alanine, Aspartic acid, Aspartic acid, Alanine, Glycine, Leucine, Valine. FOXO4-DRI is made up of a sequence of sequence data not available in the current dataset.

Receptor

BPC-157

VEGFR2 (vascular endothelial growth factor receptor 2) on endothelial cells, with downstream eNOS and nitric-oxide–mediated signaling11

FOXO4-DRI

Intracellular target is the FOXO4–p53 protein–protein interaction interface; it does not signal via a traditional cell-surface receptor38

Organism or Origin

BPC-157

Synthetic peptide derived from a naturally occurring human gastric 'Body Protection Compound' isolated from human gastric juice111

FOXO4-DRI

Synthetic peptide based on human FOXO4 transcription factor3898

Gene

BPC-157

Not assigned in the current dataset.

FOXO4-DRI

FOXO4